首页> 外文期刊>Clinical Pediatrics >Antipyretic Efficacy and Safety of Ibuprofen Versus Acetaminophen Suspension in Febrile Children: Results of 2 Randomized, Double-Blind, Single-Dose Studies
【24h】

Antipyretic Efficacy and Safety of Ibuprofen Versus Acetaminophen Suspension in Febrile Children: Results of 2 Randomized, Double-Blind, Single-Dose Studies

机译:布洛芬的退热疗效和安全性对乙酰氨基酚悬浮液在发热儿童中:2种随机,双盲,单剂量研究的结果

获取原文
获取原文并翻译 | 示例
       

摘要

Two blinded single-dose studies randomized children 6 months to 11 years old with fever to receive ibuprofen (IBU) pediatric suspension 7.5 mg/kg or acetaminophen (APAP) suspension 10 to 15 mg/kg. The primary efficacy parameter was time-weighted sum of temperature differences (TWSTD) from baseline through 8 hours for each study. Secondary end points included TWSTD from baseline through 6 hours, time to onset and duration of temperature control, and proportion with temperature control. Studies were pooled for post hoc analyses of efficacy and adverse event end points. The primary efficacy parameter significantly favored IBU over APAP in study 1 and the pooled analysis (both P < .001), but was not significant in study 2. Onset of temperature control significantly favored IBU in study 2 (P = .007). Individual and pooled secondary efficacy outcomes supported significant advantages (P < .05) of IBU over APAP. IBU pediatric suspension provided greater temperature reduction versus acetaminophen in febrile children, with a comparable safety profile.
机译:两种盲目的单剂量研究随机儿童6个月至11岁,发烧以接受布洛芬(IBU)儿科悬浮液7.5mg / kg或乙酰氨基酚(Apap)悬浮液10至15mg / kg。主要疗效参数是从基线到每项研究8小时的基线时加权温度差(TWSTD)。次要终点包括从基线到6小时的TWSTD,时间开始和温度控制的持续时间,以及温度控制比例。合并研究疗效和不良事件终点的后HOC分析。初级疗效参数在研究1和汇总分析中显着获得IBU的APAP和P <.001),但在研究中并不显着。在研究中,温度控制的发作显着优化IBU(P = .007)。个人和汇集的二次疗效结果支持IBU的显着优势(P <.05)。 IBU儿科悬浮液提供了较高的可食用儿童对乙酰氨基酚,具有可比的安全性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号